Navigation Links
Labopharm announces details for first quarter results conference call and annual meeting
Date:5/1/2008

LAVAL, QC, May 1 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the dates and times of its first quarter fiscal 2008 results conference call and Annual Meeting of Shareholders.

First Quarter Results Conference Call

On Thursday, May 8 at 8:30 a.m. (ET) Labopharm will host a conference call to discuss its first quarter 2008 financial results. Labopharm will report its first quarter 2008 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3428 or 1-800-731-5774. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, May 15, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21270272 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

Annual Meeting of Shareholders

Labopharm will hold its Annual Meeting of Shareholders on Thursday, May 8 at 11:00 am ET at the Montreal Museum of Fine Arts, Maxwell-Cummings Auditorium, 1379 Sherbrooke Street West, Montreal, Quebec.

A live webcast of the meeting will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the meeting to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the outcomes of clinical trials, the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
2. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
3. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
4. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
5. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
6. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
7. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
8. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
9. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
10. Labopharm Reports Results for Third Quarter Fiscal 2007
11. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... A newly ... rely heavily on their access to trusted resources, both in face-to-face interactions and online. ... Men of Color,” researchers concluded that the creative use of mobile digital devices can ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... 2016 increased by 9.3 million people, or 10% over last year, according to ... people covered under group policies was comparatively stable, with a slight decrease in ...
(Date:5/24/2016)... ... May 24, 2016 , ... Controlling and maintaining the home’s water heater just ... Aquanta Water Heater Controller , a first-of-its-kind system that enables remote and convenient ... the Nest thermostat does for HVAC systems, Aquanta gives users a much more efficient, ...
(Date:5/24/2016)... ... 2016 , ... The Dream Builders Project, a 501(c)3 nonprofit organization based in ... in Tijuana, Mexico on Saturday, May 21st. The volunteers took the children out for ... More than 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day ...
(Date:5/24/2016)... ... May 24, 2016 , ... Since 1946, the doctors and ... From the moment a patient arrives at the office, the staff will make ... each and every patient to create a complete dental treatment plan that is unique ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 20, 2016 ReportsnReports.com adds ... Medical Devices of its online business intelligence library. ... the current state of the Titrator industry. The ... like definitions, classifications, Specifications, applications and industry chain ... like Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost ...
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/19/2016)... May 19, 2016 According to a new ... G7 Countries, (U.S., Germany , France ... , and Japan )", published by MarketsandMarkets, ... at a CAGR of 13.9% from 2016 to 2021. ... 14 market data Tables spread through 26 Pages and in-depth TOC ...
Breaking Medicine Technology: